This study reports the use of lamotrigine, largely as add-on therapy, in 34 children, adolescents and adults with brain damage and resistant seizures. Seventy-four percent of the patients showed a greater than 50% improvement in seizure control with 35% becoming seizure free. This improvement in seizure control was associated with an enhanced quality of life in 65% of the patients as assessed by improved alertness, mobility, speech and independence. It was possible to reduce 36% of the pre-existing antiepileptic drugs and the side effect profile of lamotrigine was very good. It is proposed that lamotrigine may be a particularly useful antiepileptic drug in this particular group of patients.
INTRODUCTION
Lamotrigine has been found to be helpful in a substantial number of children and adults with difficult epilepsy 1-4 including both partial and generalized seizures. In addition, Besag t has demonstrated that lamotrigine can improve alertness and cognition, possibly related to a decrease in the number of spike and wave events rather than overt seizures. This phenomenon has been confirmed in adults by Smith et aL 5 who have demonstrated improved mastery and happiness with the addition of lamotrigine (LTG) to existing antiepileptic drug (AED) therapy. As a result of these findings, LTG has been used in a group of children, adolescents and young adults with intellectual and physical disability paying particular attention to improvements in seizure control, changes in alertness and quality of life, the withdrawal of pre-existing AEDs and drug side-effects. The present report is an open, uncontrolled study reflecting day-to-day clinical practice in this particular group of patients.
PATIENTS AND METHODS
Thirty-four patients aged 3-26 years with brain damage and subsequent epilepsy are reported.
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All had taken lamotrigine for at least 6 months, except six patients in whom LTG was ceased, either due to side-effects or a lack of effect. This latter was defined as an absence of improvement in seizure control over at least 4 months.
Because of the known interaction between lamotrigine and sodium valproate, with the latter inhibiting the metabolism of the former, increasing its half-life and blood levels, LTG was introduced slowly. In the first six patients, LTG was commenced at a dose of 25 mg every other day increasing the dose every 2 weeks. Due to the occurrence of a rash in one of these patients, the introductory dosage schedule was thereafter slowed down. In subsequent 30 patients commenced on the drug, a schedule slower than that recommended by the manufacturers was employed, commencing with a dose of 12.5 mg every third day in patients also taking sodium valproate. The dose was increased every 2 weeks to: 12.5 mg every second day, 12.5 mg twice daily, 12.5 mg mane and 25 mg nocte, 25 mg twice daily, 25 mg mane and 60 mg nocte, 50 mg b.d., 50 mg mane and 100 mg nocte, 100 mg twice daily and so on. Since the introduction of this slow introductory scheme, there have been no rashes and there has been no noticeable drowsiness observed. In patients not taking sodium valproate, LTG was introduced more rapidly commencing with 12.5 mg or 25 mg daily, still increasing the dose every 2 weeks.
Seizure control was assessed against baseline seizure frequency over the preceding 3-6 months. In some patients, especially those with myoclonic seizures, the seizures were so frequent that they could not be accurately recorded. Most of the patients had intractable seizures and their parents or carers had been keeping regular seizure records whilst attending the author's clinic. Seizure control was assessed as:
Seizure eradication, no seizures for over 6 months.
Ninety per cent seizure reduction, very sporadic seizures in patients who were previously having numerous (at least daily) seizures.
Greater than 75% seizure reduction. Greater than 50% seizure reduction. Less than 50% seizure reduction.
No effect. Deterioration in seizure control. The patients were followed up regularly, every 1 to 2 months, and parents and carers were asked about potential drug side-effects bearing in mind the difficulty in detecting these in this particular patient group. In particular, the frequency of rash was sought and signs of carbamazepine (CBZ) intoxication usually manifest by diplopia, dizziness and ataxia (where applicable), but also nausea, vomiting and drowsiness in this particular group of patients, due to an interaction with LTG 6-8. Improvements in quality of life were assessed by parents, carers and physician observation and were manifest by improved alertness, cognition and general functioning. Whilst this approach may appear scientifically 'soft', the changes were quite striking, but could not be assessed in a quantitative fashion.
AED blood level monitoring was carried out when clinically indicated but LTG concentrations were not measured as there is little relationship between serum concentrations and seizure control 9"]°. Pre-existing AEDs were withdrawn, on clinical grounds, where possible.
RESULTS
The results are presented firstly for all the patients and subsequently for the 15 children, 13 adolescents and young adults and finally for the 6 patients in whom LTG therapy was ceased.
All patients
There were 34 patients, of whom 19 were male. Their mean age was 14.4+6.3 (range, 3-26 years) and the duration of epilepsy was 12.1 + 6.5 (range, 0.5-24 years). Excluding the 6 patients in whom LTG therapy was ceased, the mean dose of LTG was 5.7 + 2.9 (range, 0.8-10.4mg/kg/day and the duration of LTG therapy was 1.0 + 0.4 (range, 0.5-2.0 years).
The overall results are shown in Table 1 with 76.6% of patients exhibiting a >50% improvement in seizure control and 35.3% showing complete seizure eradication. At the commencement of the study, the 34 patients were taking a total of 69 AEDs of which 25 (36.2%) were withdrawn during the study and nine AEDs (13%) were reduced in dosage. With regard to side effects, LTG intoxication (overdosage) occurred in 5 patients, a rash in 1 patient, a stroke-like event in 1 patient and marked insomnia in a final patient. These side-effects will be mentioned in more detail when those patients who ceased treatment are dicusssed.
In terms of quality of life, a demonstrable and often quite striking improvement was seen in 22 of the patients (64.7%).
Children
Of the 15 children (14 years of age or younger), all the patients showed a >50% improvement in seizure control with 40% of the children becoming seizure free. Three of the patients were commenced on LTG monotherapy; two of them, twin girls with cerebral palsy, would have been commenced on sodium valproate but for preexisting alopecia and a 4-year-old boy with mild cerebral palsy was commenced on LTG for its potential cognitive benefits which have been realized.
Eleven AEDs were withdrawn, the more Table 1 : Overall results in terms of seizure control in the 34 patients studied. The number of patients are shown in brackets.
Complete seizure eradication (12) 35.3% >90% improvement in seizure control (5) 14.7% >75% improvement in seizure conrtrol (5) 14.7% >50% improvement in seizure control (4) 11.8% <50% improvement in seizure control (1) 2.9% No effect, but still taking LTG (1) 2.9% No effect, LTG withdrawn (4) 11.8% Side effects, LTG withdrawn (2) 5.8%
common being clobazam, whilst five AEDs were reduced, most frequently sodium valproate. Four patients exhibited LTG intoxication due to therapeutic overdosage, but no other side-effects were observed. Twelve of the children (80%) exhibited an improvement in quality of life, especially manifest by increased alertness, responsiveness and where possible, enhanced speech and mobility.
Adolescents and young adults
Eleven of the 13 patients (84.6%) showed a >50% improvement in seizure control with 46% becoming seizure free. One patient has shown a slight improvement in seizure control, but is much more alert and responsive. The final patient has not shown any response and the LTG dose has recently been increased. If there is no effect over the next few months, LTG will be withdrawn. Fourteen AEDs were withdrawn, the most common being carbamazepine with four AEDs being reduced, especially sodium valproate. One patient became intoxicated with LTG, manifest by drowsiness, which resolved by halving the dose of sodium valproate. Ten of the patients (77%) showed an improvement in quality of life manifest by increased alertness and functional independence.
Ceased treatment groups
There were six pateints in this group. Their mean age was 15.3 + 5.3 (range, 9-25 years) and they had had epilepsy for 13.1 +5.5 (range, 7-24 years). Four of the patients showed no response to LTG over 4-12 months, hence the drug was withdrawn. One of these patients developed quite marked insomnia which resolved on withdrawing LTG. One patient developed a rash within 2 weeks of introducing LTG. With hindsight and subsequent experience, LTG was introduced too rapidly. The final patient developed a stroke-like illness with a transient left hemiplegia after four doses of 25mg LTG daily. This was not associated with any seizures and a cerebral CT scan was normal.,Lamotrigine was ceased and the signs resolved in 24 hours. Again with experience, LTG was introduced too rapidly, and may have been the cause of this symptomatology.
DISCUSSION
Due to the relatively recent availability of lamotrigine and the paucity of data in this particular group of patients, the discussion will perforce be brief. Seemingly the only existing data is an abstract by Hosking et al ~1 who reported a >50% decrease in seizure frequency over a 12-week period in 35% of 118 children with severe developmental abnormalities. These authors also observed an improvement in learning and behaviour independent of seizure control.
The present data, albeit open and uncontrolled, strongly suggests that lamotrigine is a useful antiepileptic drug both as add-on therapy and as monotherapy in this particular group of patients who often have seizures which are difficult to control. Only eight of the 34 patients (23.5%) did not show a >50% improverfient in seizure control, whilst 35.3% of the patients became seizure free and a further 29.5% showed a >75% improvement in seizure control. When these observations are associated with an improvement in quality of life in 64.7% of patients, it is proposed that these are quite encouraging results in this group of patients. As already mentioned, the 'quality of life' assessment was qualitative and not quantitative. The changes however were striking and very obvious to all involved in the patients' management. The present study does not contribute to explaining these quite often remarkable cognitive changes, but does support the observations of Besag ~ and Hosking et al ~, that they may occur independent of control of overt seizures. Further studies are planned to investigate this further in a separate group of similar patients.
Despite the difficulty in assessing side-effects in this particular group of patients, the side effect profile of LTG was excellent. There were two patients with significant side-effects; a rash and a stroke-like illness, and another patient who developed insomnia. Five patients were .LTG intoxicated due to physician over-enthusiasm. In all these patients, LTG or VPA dosage reduction resolved the problem.
Also of importance, it was the ability to withdraw 36.2% of the original AEDs and reduce the dose in a further 13% of AEDs. Based on experience in this study and a preceding one ~2, it is becoming apparent that it is difficult to withdraw sodium valproate in this and other patient groups, without a recurrence in seizures. The relationship between LTG and VPA seems more complex than purely a pharmacokinetic interaction and as suggested by Ferrie and Panayiotopoulos 13 there may be a pharmacodynamic interaction between these two drugs. Whatever the cause, there appears to be a therapeutic interaction between VPA and LTG which is beneficial to the patient and allows the use of a lower dose of LTG which could be cost effective. It may be that the use of VPA and LTG in combination represents rational polytherapy.
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